Novel antivirals for HCV-associated lymphomas

Abstract

In this issue of Blood, Arcaini et al have identified that patients with indolent B-cell non-Hodgkin lymphomas (NHLs) associated with chronic hepatitis C virus (HCV) infection, particularly those with marginal zone lymphomas (MZLs), can achieve both virologic and lymphoma responses when treated with highly effective, novel HCV eradication therapy.1